TEGOSCIENCE INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16,420 KRW | +0.98% |
|
-6.17% | +12.01% |
| 2023 | TegoScience Inc.(KOSDAQ:A191420) dropped from S&P Global BMI Index | CI |
| 2023 | TegoScience Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
| Sales 2022 | 7.68B 5.57M | Sales 2023 | 7.77B 5.64M | Capitalization | 117B 85.22M |
|---|---|---|---|---|---|
| Net income 2022 | 265M 192K | Net income 2023 | -2.32B -1.69M | EV / Sales 2022 | 9.97 x |
| Net cash position 2022 | 21.16B 15.36M | Net cash position 2023 | 19.37B 14.06M | EV / Sales 2023 | 12.6 x |
| P/E ratio 2022 |
370
x | P/E ratio 2023 |
-50.5
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 56.75% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.98% | ||
| 1 week | -6.17% | ||
| Current month | -9.83% | ||
| 1 month | -25.19% | ||
| 3 months | +0.12% | ||
| 6 months | +22.54% | ||
| Current year | +12.01% |
1 week
15 770.00
17 840.00
1 month
15 770.0026 100.00
Current year
10 710.0026 100.00
1 year
7 430.0026 100.00
3 years
7 430.0031 300.00
5 years
7 430.0037 200.00
10 years
7 430.0073 500.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sae-Wha Jeon
FOU | Founder | 58 | 01-03-19 |
| 61 | - | ||
Han-Kyu Jang
BRD | Director/Board Member | 51 | 01-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sae-Wha Jeon
FOU | Founder | 58 | 01-03-19 |
Jae-Wook Jeon
FOU | Founder | 61 | 01-03-19 |
Han-Kyu Jang
BRD | Director/Board Member | 51 | 01-04-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-11 | 16,420 | +0.98% | 14,003 |
| 24-06-10 | 16,260 | -5.36% | 60,639 |
| 24-06-07 | 17,180 | -1.66% | 7,298 |
| 24-06-05 | 17,470 | +0.69% | 5,897 |
| 24-06-04 | 17,350 | -0.86% | 17,677 |
End-of-day quote Korea S.E., June 10, 2024
More quotes
Tego Science,Inc. is a Korea-based company mainly engaged in the research and development, manufacture and distribution of wound-healing skin cell therapy products. The Companyâs products mainly consist of cell therapy products, and laboratory cultured skin models.
Sector
Pharmaceuticals
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +12.01% | 94.72M | |
| -0.12% | 92.26B | |
| -2.63% | 38.11B | |
| -12.76% | 32.9B | |
| +66.54% | 26.51B | |
| -13.02% | 15.75B | |
| -5.27% | 13.36B | |
| -10.50% | 11.65B | |
| -49.11% | 10.12B | |
| +187.82% | 9.78B |
- Stock Market
- Equities
- A191420 Stock
